Yes, Yescarta is a CAR T-cell therapy.
What is Yescarta exactly?
Yescarta (axicabtagene ciloleucel) is an autologous CAR T-cell therapy approved by the FDA for treating certain blood cancers, including relapsed or refractory large B-cell lymphoma after at least two prior therapies.[1] It uses a patient's own T cells, genetically modified in a lab to express chimeric antigen receptors (CARs) that target CD19 on cancer cells.
How does CAR T-cell therapy work?
CAR T therapy involves extracting T cells from a patient, engineering them to recognize specific cancer proteins via CARs, expanding them in the lab, and infusing them back. Yescarta follows this process, with the CAR directed against CD19 to trigger T-cell attack on lymphoma cells.[1]
What conditions is Yescarta approved for?
FDA approvals include:
- Relapsed or refractory large B-cell lymphoma after two or more systemic therapies (2017).
- Relapsed or refractory large B-cell lymphoma within 12 months of first-line chemoimmunotherapy (2021).
- Earlier use in second-line therapy for ineligible patients (2022).[1]
Who makes Yescarta and what's its development timeline?
Gilead Sciences manufactures Yescarta through its Kite Pharma subsidiary. Initial FDA approval came in October 2017, following ZUMA-1 trial data showing 82% overall response rate.[1]
How does Yescarta compare to other CAR T therapies?
| Therapy | Manufacturer | Primary Target | Key Approvals |
|---------|--------------|----------------|--------------|
| Yescarta (axi-cel) | Gilead/Kite | CD19 | Large B-cell lymphoma (3+ lines), earlier lines |
| Kymriah (tisa-cel) | Novartis | CD19 | ALL, lymphoma (3+ lines) |
| Breyanzi (liso-cel) | Bristol Myers Squibb | CD19 | Large B-cell lymphoma (2+ lines) |
| Tecartus (brexu-cel) | Gilead/Kite | CD19 | Mantle cell lymphoma, ALL |
Yescarta often shows higher early response rates but similar long-term outcomes to peers like Kymriah.[1]
What are common side effects and risks?
Patients face cytokine release syndrome (CRS, up to 94% incidence, mostly low-grade), neurologic toxicities (e.g., encephalopathy), infections, and cytopenias. Severe CRS or neurotoxicity occurs in 13-15% of cases, managed with tocilizumab or supportive care.[1]
When does Yescarta's patent protection end?
Key U.S. patents on Yescarta's composition and manufacturing expire between 2033 and 2035, per DrugPatentWatch data, with ongoing challenges from generics. Exclusivity as an orphan drug ends around 2024-2025, but patents block biosimilars.[2]
[1]: FDA.gov - Yescarta prescribing information and approval history (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-relapsed-or-refractory-large-b-cell-lymphoma)
[2]: DrugPatentWatch.com - Yescarta patents (https://www.drugpatentwatch.com/p/tradename/YESCARTA)